Helical tomotherapy with simultaneous integrated boost dose painting for the treatment of synchronous primary cancers involving the head and neck

A. M. Chen, Megan E Daly, J. Cui, H. O. Wooten, D Gregory Farwell, J. A. Purdy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To demonstrate the feasibility of helical tomotherapy (HT)-based intensity-modulated radiotherapy (IMRT) for the treatment of synchronous primary cancers arising from the head and neck.

Methods: 14 consecutive patients with histologically proven squamous cell carcinoma of the head and neck were determined to have a second primary cancer in the upper aerodigestive tract on further evaluation and were treated with HT using simultaneous integrated boost IMRT. Megavoltage CT scans were acquired daily as part of an image-guided registration protocol. Concurrent platinum-based systemic therapy was given to nine patients (64%).

Results: HT resulted in durable local control in 21 of the 28 primary disease sites irradiated, including a complete clinical and radiographic response initially observed at 17 of the 20 sites with gross tumour. The mean displacements to account for interfraction motion were 2.44± 1.25, 2.92±1.09 and 2.31±1.70mm for the medial-lateral (ML), superior-inferior (SI) and anteroposterior (AP) directions, respectively. Table shifts of >3mm occurred in 19%, 20% and 22% of the ML, SI and AP directions, respectively. The 2-year estimates of overall survival, local-regional control and progression-free survival were 58%, 73% and 60%, respectively.

Conclusion: The effectiveness of HT for the treatment of synchronous primary cancers of the head and neck was demonstrated.

Advances in knowledge: HT is a feasible option for synchronous primary cancers of the head and neck and can result in long-term disease control with acceptable toxicity in appropriately selected patients.

Original languageEnglish (US)
Article number20130697
JournalBritish Journal of Radiology
Volume87
Issue number1040
DOIs
StatePublished - Aug 1 2014

Fingerprint

Intensity-Modulated Radiotherapy
Paintings
Head and Neck Neoplasms
Therapeutics
Second Primary Neoplasms
Platinum
Disease-Free Survival
Survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Helical tomotherapy with simultaneous integrated boost dose painting for the treatment of synchronous primary cancers involving the head and neck. / Chen, A. M.; Daly, Megan E; Cui, J.; Wooten, H. O.; Farwell, D Gregory; Purdy, J. A.

In: British Journal of Radiology, Vol. 87, No. 1040, 20130697, 01.08.2014.

Research output: Contribution to journalArticle

@article{699fcc1a927c4f7dbdc597357c0eb05f,
title = "Helical tomotherapy with simultaneous integrated boost dose painting for the treatment of synchronous primary cancers involving the head and neck",
abstract = "Objective: To demonstrate the feasibility of helical tomotherapy (HT)-based intensity-modulated radiotherapy (IMRT) for the treatment of synchronous primary cancers arising from the head and neck.Methods: 14 consecutive patients with histologically proven squamous cell carcinoma of the head and neck were determined to have a second primary cancer in the upper aerodigestive tract on further evaluation and were treated with HT using simultaneous integrated boost IMRT. Megavoltage CT scans were acquired daily as part of an image-guided registration protocol. Concurrent platinum-based systemic therapy was given to nine patients (64{\%}).Results: HT resulted in durable local control in 21 of the 28 primary disease sites irradiated, including a complete clinical and radiographic response initially observed at 17 of the 20 sites with gross tumour. The mean displacements to account for interfraction motion were 2.44± 1.25, 2.92±1.09 and 2.31±1.70mm for the medial-lateral (ML), superior-inferior (SI) and anteroposterior (AP) directions, respectively. Table shifts of >3mm occurred in 19{\%}, 20{\%} and 22{\%} of the ML, SI and AP directions, respectively. The 2-year estimates of overall survival, local-regional control and progression-free survival were 58{\%}, 73{\%} and 60{\%}, respectively.Conclusion: The effectiveness of HT for the treatment of synchronous primary cancers of the head and neck was demonstrated.Advances in knowledge: HT is a feasible option for synchronous primary cancers of the head and neck and can result in long-term disease control with acceptable toxicity in appropriately selected patients.",
author = "Chen, {A. M.} and Daly, {Megan E} and J. Cui and Wooten, {H. O.} and Farwell, {D Gregory} and Purdy, {J. A.}",
year = "2014",
month = "8",
day = "1",
doi = "10.1259/bjr.20130697",
language = "English (US)",
volume = "87",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1040",

}

TY - JOUR

T1 - Helical tomotherapy with simultaneous integrated boost dose painting for the treatment of synchronous primary cancers involving the head and neck

AU - Chen, A. M.

AU - Daly, Megan E

AU - Cui, J.

AU - Wooten, H. O.

AU - Farwell, D Gregory

AU - Purdy, J. A.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Objective: To demonstrate the feasibility of helical tomotherapy (HT)-based intensity-modulated radiotherapy (IMRT) for the treatment of synchronous primary cancers arising from the head and neck.Methods: 14 consecutive patients with histologically proven squamous cell carcinoma of the head and neck were determined to have a second primary cancer in the upper aerodigestive tract on further evaluation and were treated with HT using simultaneous integrated boost IMRT. Megavoltage CT scans were acquired daily as part of an image-guided registration protocol. Concurrent platinum-based systemic therapy was given to nine patients (64%).Results: HT resulted in durable local control in 21 of the 28 primary disease sites irradiated, including a complete clinical and radiographic response initially observed at 17 of the 20 sites with gross tumour. The mean displacements to account for interfraction motion were 2.44± 1.25, 2.92±1.09 and 2.31±1.70mm for the medial-lateral (ML), superior-inferior (SI) and anteroposterior (AP) directions, respectively. Table shifts of >3mm occurred in 19%, 20% and 22% of the ML, SI and AP directions, respectively. The 2-year estimates of overall survival, local-regional control and progression-free survival were 58%, 73% and 60%, respectively.Conclusion: The effectiveness of HT for the treatment of synchronous primary cancers of the head and neck was demonstrated.Advances in knowledge: HT is a feasible option for synchronous primary cancers of the head and neck and can result in long-term disease control with acceptable toxicity in appropriately selected patients.

AB - Objective: To demonstrate the feasibility of helical tomotherapy (HT)-based intensity-modulated radiotherapy (IMRT) for the treatment of synchronous primary cancers arising from the head and neck.Methods: 14 consecutive patients with histologically proven squamous cell carcinoma of the head and neck were determined to have a second primary cancer in the upper aerodigestive tract on further evaluation and were treated with HT using simultaneous integrated boost IMRT. Megavoltage CT scans were acquired daily as part of an image-guided registration protocol. Concurrent platinum-based systemic therapy was given to nine patients (64%).Results: HT resulted in durable local control in 21 of the 28 primary disease sites irradiated, including a complete clinical and radiographic response initially observed at 17 of the 20 sites with gross tumour. The mean displacements to account for interfraction motion were 2.44± 1.25, 2.92±1.09 and 2.31±1.70mm for the medial-lateral (ML), superior-inferior (SI) and anteroposterior (AP) directions, respectively. Table shifts of >3mm occurred in 19%, 20% and 22% of the ML, SI and AP directions, respectively. The 2-year estimates of overall survival, local-regional control and progression-free survival were 58%, 73% and 60%, respectively.Conclusion: The effectiveness of HT for the treatment of synchronous primary cancers of the head and neck was demonstrated.Advances in knowledge: HT is a feasible option for synchronous primary cancers of the head and neck and can result in long-term disease control with acceptable toxicity in appropriately selected patients.

UR - http://www.scopus.com/inward/record.url?scp=84907485633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907485633&partnerID=8YFLogxK

U2 - 10.1259/bjr.20130697

DO - 10.1259/bjr.20130697

M3 - Article

C2 - 24884726

AN - SCOPUS:84907485633

VL - 87

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1040

M1 - 20130697

ER -